Comparative evaluation of urinary PCA3 and TMPRSS2: Erg scores and serum PHI in predicting prostate cancer aggressiveness

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13299-13316

  Tallon, Lucile ^a,b   Luangphakdy, Devillier ^a,b   Ruffion, Alain ^a,b,c   Colombel, Marc ^b,c,d   Devonec, Marian ^a,b   Champetier, Denis ^a   Paparel, Philippe ^a,b   Decaussin Petrucci, Myriam ^a,b,c   Perrin, Paul ^a,b   Vlaeminck Guillem, Virginie ^a,b,e  

^a HOSPICES CIVILS DE LYON   (France)

^b Department of Medicine and Pharmacy ^*  (France)

^c UNIVERSITÉ LYON 1   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

Aggressiveness; PCA3; PHI; Prostate cancer; Radical prostatectomy; TMPRSS2 ERG gene fusion; Urine biomarker

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PEPTIDE HISTIDINE ISOLEUCINE; PROSTATE CANCER ANTIGEN 3, HUMAN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; ERG GENE; GENE FUSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATE HEALTH INDEX; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; TRANSMEMBRANE PROTEASE SERINE 2 GENE; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GENE; TUMOR VOLUME; URINE LEVEL; AREA UNDER THE CURVE; BLOOD; CANCER STAGING; EVALUATION STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; STATISTICAL MODEL; URINE;

AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOLOGICAL MARKERS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE PHI; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SERINE ENDOPEPTIDASES;

EID: 84905241494     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813299     Document Type: Article

References (45)

1. Wilt, T. J.; Ahmed, H. U. Prostate cancer screening and the management of clinically localized disease. BMJ 2013, 346, f325. doi: 10. 1136/bmj. f325.
2. Bussemakers, M. J.; van Bokhoven, A.; Verhaegh, G. W.; Smit, F. P.; Karthaus, H. F.; Schalken, J. A.; Debruyne, F. M.; Ru, N.; Isaacs, W. B. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999, 59, 5975-5979.
3. Hessels, D.; Klein Gunnewiek, J. M.; van Oort, I.; Karthaus, H. F.; van Leenders, G. J.; van Balken, B.; Kiemeney, L. A.; Witjes, J. A.; Schalken, J. A. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44, 8-15.
4. Groskopf, J.; Aubin, S. M.; Deras, I. L.; Blase, A.; Bodrug, S.; Clark, C.; Brentano, S.; Mathis, J.; Pham, J.; Meyer, T.; et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 2006, 52, 1089-1095.
5. Auprich, M.; Bjartell, A.; Chun, F. K.; de la Taille, A.; Freedland, S. J.; Haese, A.; Schalken, J.; Stenzl, A.; Tombal, B.; van der Poel, H. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur. Urol. 2011, 60, 1045-1054.
6. Vlaeminck-Guillem, V.; Ruffion, A.; Andre, J.; Devonec, M.; Paparel, P. Urinary prostate cancer 3 test: Toward the age of reason? Urology 2010, 75, 447-453.
7. Tomlins, S. A.; Rhodes, D. R.; Perner, S.; Dhanasekaran, S. M.; Mehra, R.; Sun, X. W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310, 644-648.
8. Tomlins, S. A.; Bjartell, A.; Chinnaiyan, A. M.; Jenster, G.; Nam, R. K.; Rubin, M. A.; Schalken, J. A. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur. Urol. 2009, 56, 275-286.
9. Pettersson, A.; Graff, R. E.; Bauer, S. R.; Pitt, M. J.; Lis, R. T.; Stack, E. C.; Martin, N. E.; Kunz, L.; Penney, K. L.; Ligon, A. H.; et al. The TMPRSS2: ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis. Cancer Epidemiol. Biomark. Prev. 2012, 21, 1497-1509.
10. Hessels, D.; Smit, F. P.; Verhaegh, G. W.; Witjes, J. A.; Cornel, E. B.; Schalken, J. A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 2007, 13, 5103-5108.
11. Laxman, B.; Tomlins, S. A.; Mehra, R.; Morris, D. S.; Wang, L.; Helgeson, B. E.; Shah, R. B.; Rubin, M. A.; Wei, J. T.; Chinnaiyan, A. M. Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006, 8, 885-888.
12. Tomlins, S. A.; Aubin, S. M.; Siddiqui, J.; Lonigro, R. J.; Sefton-Miller, L.; Miick, S.; Williamsen, S.; Hodge, P.; Meinke, J.; Blase, A.; et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 2011, 3, 94ra72. doi: 10. 1126/scitranslmed. 3001970.
13. Le, B. V.; Griffin, C. R.; Loeb, S.; Carvalhal, G. F.; Kan, D.; Baumann, N. A.; Catalona, W. J. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J. Urol. 2010, 183, 1355-1359.
14. Jansen, F. H.; van Schaik, R. H.; Kurstjens, J.; Horninger, W.; Klocker, H.; Bektic, J.; Wildhagen, M. F.; Roobol, M. J.; Bangma, C. H.; Bartsch, G. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur. Urol. 2010, 57, 921-927.
15. Guazzoni, G.; Nava, L.; Lazzeri, M.; Scattoni, V.; Lughezzani, G.; Maccagnano, C.; Dorigatti, F.; Ceriotti, F.; Pontillo, M.; Bini, V.; et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2. 0 and 10 ng/mL: Results of a prospective study in a clinical setting. Eur. Urol. 2011, 60, 214-222.
16. Stephan, C.; Vincendeau, S.; Houlgatte, A.; Cammann, H.; Jung, K.; Semjonow, A. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin. Chem. 2013, 59, 306-314.
17. Filella, X.; Foj, L.; Maria Auge, J.; Molina, R.; Alcover, J. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clin. Chem. Lab. Med.: CCLM/FESCC 2014, doi: 10. 1515/cclm-2014-0027.
18. Ferro, M.; Bruzzese, D.; Perdona, S.; Marino, A.; Mazzarella, C.; Perruolo, G.; D'Esposito, V.; Cosimato, V.; Buonerba, C.; di Lorenzo, G.; et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/mL. PLoS One 2013, 8, e67687.
19. Ferro, M.; Bruzzese, D.; Perdona, S.; Mazzarella, C.; Marino, A.; Sorrentino, A.; di Carlo, A.; Autorino, R.; di Lorenzo, G.; Buonerba, C.; et al. Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin. Chim. Acta 2012, 413, 1274-1278.
20. Perdona, S.; Bruzzese, D.; Ferro, M.; Autorino, R.; Marino, A.; Mazzarella, C.; Perruolo, G.; Longo, M.; Spinelli, R.; di Lorenzo, G.; et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013, 73, 227-235.
21. Scattoni, V.; Lazzeri, M.; Lughezzani, G.; de Luca, S.; Passera, R.; Bollito, E.; Randone, D.; Abdollah, F.; Capitanio, U.; Larcher, A.; et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J. Urol. 2013, 190, 496-501.
22. Stephan, C.; Jung, K.; Semjonow, A.; Schulze-Forster, K.; Cammann, H.; Hu, X.; Meyer, H. A.; Bogemann, M.; Miller, K.; Friedersdorff, F. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2: ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin. Chem. 2013, 59, 280-288.
23. Nakanishi, H.; Groskopf, J.; Fritsche, H. A.; Bhadkamkar, V.; Blase, A.; Kumar, S. V.; Davis, J. W.; Troncoso, P.; Rittenhouse, H.; Babaian, R. J. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J. Urol. 2008, 179, 1804-1809.
24. Auprich, M.; Chun, F. K.; Ward, J. F.; Pummer, K.; Babaian, R.; Augustin, H.; Luger, F.; Gutschi, S.; Budaus, L.; Fisch, M.; et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur. Urol. 2011, 59, 96-105.
25. Durand, X.; Xylinas, E.; Radulescu, C.; Haus-Cheymol, R.; Moutereau, S.; Ploussard, G.; Forgues, A.; Robert, G.; Vacherot, F.; Loric, S.; et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 2012, 110, 43-49.
26. Whitman, E. J.; Groskopf, J.; Ali, A.; Chen, Y.; Blase, A.; Furusato, B.; Petrovics, G.; Ibrahim, M.; Elsamanoudi, S.; Cullen, J.; et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 2008, 180, 1975-1978.
27. Vlaeminck-Guillem, V.; Devonec, M.; Colombel, M.; Rodriguez-Lafrasse, C.; Decaussin-Petrucci, M.; Ruffion, A. Urinary PCA3 score predicts prostate cancer multifocality. J. Urol. 2011, 185, 1234-1239.
28. Augustin, H.; Mayrhofer, K.; Pummer, K.; Mannweiler, S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate 2013, 73, 203-210.
29. Hessels, D.; van Gils, M. P.; van Hooij, O.; Jannink, S. A.; Witjes, J. A.; Verhaegh, G. W.; Schalken, J. A. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010, 70, 10-16.
30. Leyten, G. H.; Hessels, D.; Jannink, S. A.; Smit, F. P.; de Jong, H.; Cornel, E. B.; de Reijke, T. M.; Vergunst, H.; Kil, P.; Knipscheer, B. C.; et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 2014, 65, 534-542.
31. Van Gils, M. P.; Hessels, D.; Hulsbergen-van de Kaa, C. A.; Witjes, J. A.; Jansen, C. F.; Mulders, P. F.; Rittenhouse, H. G.; Schalken, J. A. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008, 68, 1215-1222.
32. Young, A.; Palanisamy, N.; Siddiqui, J.; Wood, D. P.; Wei, J. T.; Chinnaiyan, A. M.; Kunju, L. P.; Tomlins, S. A. Correlation of urine TMPRSS2: ERG and PCA3 to ERG+ and total prostate cancer burden. Am. J. Clin. Pathol. 2012, 138, 685-696.
33. Van Poppel, H.; Haese, A.; Graefen, M.; de la Taille, A.; Irani, J.; de Reijke, T.; Remzi, M.; Marberger, M. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012, 109, 360-366.
34. Liss, M. A.; Santos, R.; Osann, K.; Lau, A.; Ahlering, T. E.; Ornstein, D. K. PCA3 molecular urine assay for prostate cancer: Association with pathologic features and impact of collection protocols. World J. Urol. 2011, 29, 683-688.
35. Rostad, K.; Hellwinkel, O. J.; Haukaas, S. A.; Halvorsen, O. J.; Oyan, A. M.; Haese, A.; Budaus, L.; Albrecht, H.; Akslen, L. A.; Schlomm, T.; et al. TMPRSS2: ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009, 117, 575-582.
36. Guazzoni, G.; Lazzeri, M.; Nava, L.; Lughezzani, G.; Larcher, A.; Scattoni, V.; Gadda, G. M.; Bini, V.; Cestari, A.; Buffi, N. M.; et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur. Urol. 2012, 61, 455-466.
37. Epstein, J. I. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J. Urol. 2011, 186, 790-797.
38. Ploussard, G.; Durand, X.; Xylinas, E.; Moutereau, S.; Radulescu, C.; Forgue, A.; Nicolaiew, N.; Terry, S.; Allory, Y.; Loric, S.; et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur. Urol. 2011, 59, 422-429.
39. Mouraviev, V.; Villers, A.; Bostwick, D. G.; Wheeler, T. M.; Montironi, R.; Polascik, T. J. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy. BJU Int. 2011, 108, 1074-1085.
40. Leyten, G. H.; Wierenga, E. A.; Sedelaar, J. P.; van Oort, I. M.; Futterer, J. J.; Barentsz, J. O.; Schalken, J. A.; Mulders, P. F. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int. J. Mol. Sci. 2013, 14, 11347-11355.
41. Semjonow, A.; Kopke, T.; Eltze, E.; Pepping-Schefers, B.; Burgel, H.; Darte, C. Pre-analytical in vitro stability of [-2]proPSA in blood and serum. Clin. Biochem. 2010, 43, 926-928.
42. Chen, M. E.; Johnston, D.; Reyes, A. O.; Soto, C. P.; Babaian, R. J.; Troncoso, P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am. J. Surg. Pathol. 2003, 27, 1291-1301.
43. Vickers, A. J.; Cronin, A. M. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: Towards a decision analytic framework. Semin. Oncol. 2010, 37, 31-38.
44. Vickers, A. J.; Cronin, A. M.; Begg, C. B. One statistical test is sufficient for assessing new predictive markers. BMC Med. Res. Methodol. 2011, 11, 13. doi: 10. 1186/1471-2288-11-13.
45. Vickers, A. J.; Elkin, E. B. Decision curve analysis: A novel method for evaluating prediction models. Med. Decis. Mak. 2006, 26, 565-574.